Download MendeleyShape-Based Virtual Screening of a Billion-Compound Library Identifies Mycobacterial Lipoamide Dehydrogenase Inhibitors.
Michino, M., Beautrait, A., Boyles, N.A., Nadupalli, A., Dementiev, A., Sun, S., Ginn, J., Baxt, L., Suto, R., Bryk, R., Jerome, S.V., Huggins, D.J., Vendome, J.(2023) ACS Bio Med Chem Au 3: 507-515
- PubMed: 38144256
- DOI: https://doi.org/10.1021/acsbiomedchemau.3c00046
- Primary Citation of Related Structures:
8U0Q - PubMed Abstract:
Lpd (lipoamide dehydrogenase) in Mycobacterium tuberculosis (Mtb) is required for virulence and is a genetically validated tuberculosis (TB) target. Numerous screens have been performed over the last decade, yet only two inhibitor series have been identified. Recent advances in large-scale virtual screening methods combined with make-on-demand compound libraries have shown the potential for finding novel hits. In this study, the Enamine REAL library consisting of ∼1.12 billion compounds was efficiently screened using the GPU Shape screen method against Mtb Lpd to find additional chemical matter that would expand on the known sulfonamide inhibitor series. We identified six new inhibitors with IC 50 in the range of 5-100 μM. While these compounds remained chemically close to the already known sulfonamide series inhibitors, some diversity was found in the cores of the hits. The two most potent hits were further validated by one-step potency optimization to submicromolar levels. The co-crystal structure of optimized analogue TDI-13537 provided new insights into the potency determinants of the series.
Organizational Affiliation:
Sanders Tri-Institutional Therapeutics Discovery Institute, 1230 York Avenue, Box 122, New York, New York 10065, United States.
